Aberrant glycosylation associated with enzymes as cancer biomarkers

Clinical Proteomics

Volumn 8, Issue 1, 2011, Pages

  Meany, Danni L ^a   Chan, Daniel W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aberrant Glycosylation; Cancer Biomarkers; Enzyme; Glycan; Glycoprotein; Glycosyltransferases

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; ENDOPLASMIC RETICULUM GOLGI INTERMEDIATE COMPARTMENT PROTEIN 53; GALACTOSAMINE; GLYCAN; GLYCOPROTEIN; GLYCOSIDASE; GLYCOSYLTRANSFERASE; N ACETYLGLUCOSAMINE; PROSTATE SPECIFIC ANTIGEN; SIALYLTRANSFERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANDROGEN DEPRIVATION THERAPY; AREA UNDER THE CURVE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; ENZYME GLYCOSYLATION; FUCOSYLATION; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; LYMPH NODE METASTASIS; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84860239658     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-8-7     Document Type: Review

References (97)

1. Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Meany DL, Sokoll LJ, Chan DW, Expert Opin Med Diagn 2009 3 6 597 605 10.1517/17530050903266830 19966928
2. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. J Clin Oncol 1999 17 9 2639 2648 10561337 (Pubitemid 29415219)
3. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. J Clin Oncol 2002 20 3 719 726 10.1200/JCO.20.3.719 11821453 (Pubitemid 34111379)
4. Multiple forms of plasminogen activator in human breast tumors. O'Grady P, Lijnen HR, Duffy MJ, Cancer Res 1985 45 12 Pt 1 6216 6218 3933824 (Pubitemid 16224783)
5. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ, Cancer 1988 62 3 531 533 10.1002/1097-0142(19880801)62: 3<531::AID-CNCR2820620315>3.0.CO;2-B 3134120
6. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Janicke F, Schmitt M, Ulm K, Gossner W, Graeff H, Lancet 1989 2 8670 1049 2572788 (Pubitemid 19257967)
7. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. J Clin Oncol 2007 25 33 5287 5312 10.1200/JCO.2007.14.2364 17954709 (Pubitemid 350232263)
8. Enzymes and related proteins as cancer biomarkers: a proteomic approach. Liang SL, Chan DW, Clin Chim Acta 2007 381 1 93 97 10.1016/j.cca.2007.02.017 17382922 (Pubitemid 46719129)
9. Glycoprotein glycosylation and cancer progression. Dennis JW, Granovsky M, Warren CE, Biochim Biophys Acta 1999 1473 1 21 34 10580127
10. The sweet and sour of cancer: glycans as novel therapeutic targets. Fuster MM, Esko JD, Nat Rev Cancer 2005 5 7 526 542 10.1038/nrc1649 16069816 (Pubitemid 40942829)
11. Glycans in cancer and inflammation - potential for therapeutics and diagnostics. Dube DH, Bertozzi CR, Nat Rev Drug Discov 2005 4 6 477 488 10.1038/nrd1751 15931257 (Pubitemid 40861990)
12. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Drake PM, Cho W, Li B, Prakobphol A, Johansen E, Anderson NL, et al. Clin Chem 2010 56 2 223 236 10.1373/clinchem.2009.136333 19959616
13. Possible roles of tumor-associated carbohydrate antigens. Fukuda M, Cancer Res 1996 56 10 2237 2244 8625291 (Pubitemid 26154066)
14. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Li D, Mallory T, Satomura S, Clin Chim Acta 2001 313 1-2 15 19 10.1016/S0009-8981(01)00644-1 11694234 (Pubitemid 33016686)
15. Fucosyltransferases: differential plasma and tissue alterations in hepatocellular carcinoma and cirrhosis. Hutchinson WL, Du MQ, Johnson PJ, Williams R, Hepatology 1991 13 4 683 688 10.1002/hep.1840130412 1849114
16. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Noda K, Miyoshi E, Gu J, Gao CX, Nakahara S, Kitada T, et al. Cancer Res 2003 63 19 6282 6289 14559815 (Pubitemid 37255175)
17. A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation. Moriwaki K, Noda K, Nakagawa T, Asahi M, Yoshihara H, Taniguchi N, et al. Glycobiology 2007 17 12 1311 1320 10.1093/glycob/cwm094 17884843 (Pubitemid 350138979)
18. Enzymatic basis of sugar structures of alpha-fetoprotein in hepatoma and hepatoblastoma cell lines: correlation with activities of alpha 1-6 fucosyltransferase and N-acetylglucosaminyltransferases III and V. Ohno M, Nishikawa A, Koketsu M, Taga H, Endo Y, Hada T, et al. Int J Cancer 1992 51 2 315 317 10.1002/ijc.2910510223 1373706
19. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Zhang Z, Chan DW, Cancer Epidemiol Biomarkers Prev 2010 19 12 2995 2999 10.1158/1055-9965.EPI-10-0580 20962299
20. Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Sellers TA, Huang Y, Cunningham J, Goode EL, Sutphen R, Vierkant RA, et al. Cancer Epidemiol Biomarkers Prev 2008 17 2 397 404 10.1158/1055-9965.EPI-07-0565 18268124 (Pubitemid 351272793)
21. UDP-N-acetyl-D-galactosamine: polypeptide N- acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker. Berois N, Mazal D, Ubillos L, Trajtenberg F, Nicolas A, Sastre-Garau X, et al. J Histochem Cytochem 2006 54 3 317 328 16260590 (Pubitemid 43291276)
22. Prognostic utility of glycosyltransferase expression in breast cancer. Patani N, Jiang W, Mokbel K, Cancer Genomics Proteomics 2008 5 6 333 340 19287074
23. Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma. Gomes J, Marcos NT, Berois N, Osinaga E, Magalhaes A, Pinto-de-Sousa J, et al. J Histochem Cytochem 2009 57 1 79 86 18854599
24. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, et al. Cancer Res 2010 70 7 2759 2769 10.1158/0008-5472.CAN-09-3911 20215525
25. N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang B, et al. BMC Cancer 2010 10 123 10.1186/1471-2407-10-123 20356418
26. Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Handerson T, Camp R, Harigopal M, Rimm D, Pawelek J, Clin Cancer Res 2005 11 8 2969 2973 10.1158/1078-0432.CCR-04- 2211 15837749 (Pubitemid 40525200)
27. N-acetylglucosaminyltransferase V expression levels regulate cadherin-associated homotypic cell-cell adhesion and intracellular signaling pathways. Guo HB, Lee I, Kamar M, Pierce M, J Biol Chem 2003 278 52 52412 52424 10.1074/jbc.M308837200 14561752 (Pubitemid 38035833)
28. The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Pinho SS, Reis CA, Paredes J, Magalhaes AM, Ferreira AC, Figueiredo J, et al. Hum Mol Genet 2009 18 14 2599 2608 10.1093/hmg/ddp194 19403558
29. Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. Takahashi M, Kuroki Y, Ohtsubo K, Taniguchi N, Carbohydr Res 2009 344 12 1387 1390 10.1016/j.carres.2009.04.031 19508951
30. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW, Nat Med 2000 6 3 306 312 10.1038/73163 10700233 (Pubitemid 30148623)
31. alpha-2,3-Sialyltransferase type 3N and alpha-1,3-fucosyltransferase type VII are related to sialyl Lewis(x) synthesis and patient survival from lung carcinoma. Ogawa JI, Inoue H, Koide S, Cancer 1997 79 9 1678 1685 10.1002/(SICI)1097-0142(19970501)79:9<1678::AID-CNCR7>3.0.CO;2-8 9128982 (Pubitemid 27176348)
32. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P, Cancer Res 1998 58 18 4066 4070 9751611 (Pubitemid 28440556)
33. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Burchell J, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H, et al. Glycobiology 1999 9 12 1307 1311 10.1093/glycob/9.12.1307 10561455 (Pubitemid 30011510)
34. Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases. Petretti T, Kemmner W, Schulze B, Schlag PM, Gut 2000 46 3 359 366 10.1136/gut.46.3.359 10673297 (Pubitemid 30313387)
35. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S, et al. Glycobiology 2010 20 10 1241 1250 10.1093/glycob/cwq085 20534593
36. alpha2,3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo. Perez-Garay M, Arteta B, Pages L, de Llorens R, de Bolos C, Vidal-Vanaclocha F, et al. PLoS One 2010 5 9
37. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart AS, et al. Glycobiology 2006 16 1 54 64 16135558 (Pubitemid 43009808)
38. Clinical relevance of sialyltransferases ST6GAL-I and ST3GAL-III in gastric cancer. Gretschel S, Haensch W, Schlag PM, Kemmner W, Oncology 2003 65 2 139 145 10.1159/000072339 12931020 (Pubitemid 37025975)
39. Clinical significance of ST3Gal IV expression in human renal cell carcinoma. Saito S, Yamashita S, Endoh M, Yamato T, Hoshi S, Ohyama C, et al. Oncol Rep 2002 9 6 1251 1255 12375029
40. Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas. Schneider F, Kemmner W, Haensch W, Franke G, Gretschel S, Karsten U, et al. Cancer Res 2001 61 11 4605 4611 11389097 (Pubitemid 32685796)
41. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Ishizuka H, Nakayama T, Matsuoka S, Gotoh I, Ogawa M, Suzuki K, et al. Intern Med 1999 38 12 927 931 10.2169/internalmedicine.38.927 10628928
42. Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. Matsumoto K, Shimizu C, Arao T, Andoh M, Katsumata N, Kohno T, et al. J Proteome Res 2009 8 2 457 462 10.1021/pr800655p 19140672
43. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, et al. Cancer Epidemiol Biomarkers Prev 2010 19 5 1193 1200 10.1158/1055-9965.EPI-10-0007 20447916
44. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, et al. Glycobiology 2003 13 6 457 470 10.1093/glycob/cwg041 12626390 (Pubitemid 36665420)
45. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Ohyama C, Hosono M, Nitta K, Oh-eda M, Yoshikawa K, Habuchi T, et al. Glycobiology 2004 14 8 671 679 10.1093/glycob/cwh071 15044396 (Pubitemid 39161974)
46. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Fukushima K, Satoh T, Baba S, Yamashita K, Glycobiology 2010 20 4 452 460 10.1093/glycob/cwp197 20008118
47. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW, J Proteome Res 2009 8 2 613 619 10.1021/pr8007539 19035787
48. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. Draisma G, Boer R, Otto SJ, van der, Cruijsen IW, Damhuis RA, Schroder FH, et al. J Natl Cancer Inst 2003 95 12 868 878 10.1093/jnci/95.12.868 12813170 (Pubitemid 36833878)
49. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, et al. J Clin Oncol 1997 15 6 2322 2328 9196146 (Pubitemid 27251134)
50. Reactivity of a monoclonal antibody with human ovarian carcinoma. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC, J Clin Invest 1981 68 5 1331 1337 10.1172/JCI110380 7028788 (Pubitemid 12235035)
51. A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. Cancer Prev Res (Phila) 2011 4 3 375 383 10.1158/1940-6207.CAPR-10-0193
52. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Cancer Prev Res (Phila) 2011 4 3 365 374 10.1158/1940-6207.CAPR-10-0195
53. The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. Jacobs I, Menon U, Cancer Prev Res (Phila) 2011 4 3 299 302 10.1158/1940-6207.CAPR-11-0048
54. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Storr SJ, Royle L, Chapman CJ, Hamid UM, Robertson JF, Murray A, et al. Glycobiology 2008 18 6 456 462 10.1093/glycob/cwn022 18332077 (Pubitemid 351753549)
55. Glycoforms of CA125 antigen as a possible cancer marker. Jankovic MM, Milutinovic BS, Cancer Biomark 2008 4 1 35 42 18334732 (Pubitemid 351343910)
56. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Hakomori S, Cancer Res 1985 45 6 2405 2414 3886132 (Pubitemid 15024398)
57. Summary report on the ISOBM TD-6 workshop: analysis of 20 monoclonal antibodies against Sialyl Lewisa and related antigens. Montreux, Switzerland, September 19-24, 1997. Rye PD, Bovin NV, Vlasova EV, Molodyk AA, Baryshnikov A, Kreutz FT, et al. Tumour Biol 1998 19 5 390 420 10.1159/000030032 9701730 (Pubitemid 28384465)
58. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jorgensen J, Wolf H, et al. Clin Chem 1999 45 1 54 61 9895338 (Pubitemid 29036385)
59. The Prevalence and Nature of Glycan Alterations on Specific Proteins in Pancreatic Cancer Patients Revealed Using Antibody-Lectin Sandwich Arrays. Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE, Haab BB, Mol Cell Proteomics 2009 8 7 1697 1707 10.1074/mcp.M900135-MCP200 19377061
60. Alterations in the Serum Glycome Due to Metastatic Prostate Cancer. Kyselova Z, Mechref Y, Al Bataineh MM, Dobrolecki LE, Hickey RJ, Vinson J, et al. Journal of Proteome Research 2007 6 5 1822 1832 10.1021/pr060664t 17432893 (Pubitemid 46814506)
61. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, et al. Clin Chem 2008 54 7 1166 1175 10.1373/clinchem.2007.087148 18487288 (Pubitemid 352009693)
62. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R, Nat Med 2004 10 4 429 434 10.1038/nm1006 15152612 (Pubitemid 38508524)
63. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, et al. Mol Cell Proteomics 2009 8 5 986 994 10.1074/mcp.M800470-MCP200 19181623
64. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, et al. Hepatology 2007 46 5 1426 1435 10.1002/hep.21855 17683101 (Pubitemid 350155524)
65. Glycomic profiling of invasive and non-invasive breast cancer cells. Goetz JA, Mechref Y, Kang P, Jeng MH, Novotny MV, Glycoconj J 2009 26 2 117 131 10.1007/s10719-008-9170-4 18752066
66. N-glycomic changes in human breast carcinoma MCF-7 and T-lymphoblastoid cells after treatment with herceptin and herceptin/Lipoplex. Lattova E, Tomanek B, Bartusik D, Perreault H, J Proteome Res 2010 9 3 1533 1540 10.1021/pr9010266 20063903
67. Comprehensive clinico-glycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells. Misonou Y, Shida K, Korekane H, Seki Y, Noura S, Ohue M, et al. J Proteome Res 2009 8 6 2990 3005 10.1021/pr900092r 19292502
68. Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer. Abbott KL, Nairn AV, Hall EM, Horton MB, McDonald JF, Moremen KW, et al. Proteomics 2008 8 16 3210 3220 10.1002/pmic.200800157 18690643
69. Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Abbott KL, Lim JM, Wells L, Benigno BB, McDonald JF, Pierce M, Proteomics 2010 10 3 470 481 10.1002/pmic.200900537 19953551
70. Targeted glycoproteomic identification of biomarkers for human breast carcinoma. Abbott KL, Aoki K, Lim JM, Porterfield M, Johnson R, O'Regan RM, et al. J Proteome Res 2008 7 4 1470 1480 10.1021/pr700792g 18271524
71. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, et al. Proc Natl Acad Sci USA 2005 102 3 779 784 10.1073/pnas.0408928102 15642945 (Pubitemid 40282742)
72. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, et al. J Hepatol 2005 43 6 1007 1012 10.1016/j.jhep.2005.05.028 16137783 (Pubitemid 41627986)
73. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, et al. J Proteome Res 2006 5 2 308 315 10.1021/pr050328x 16457596 (Pubitemid 43224256)
74. Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L, Kopenhaver B, et al. J Proteome Res 2009 8 2 595 602 10.1021/pr800752c 19099421
75. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, et al. Cancer Epidemiol Biomarkers Prev 2009 18 6 1914 1921 10.1158/1055-9965. EPI-08-0980 19454616
76. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, et al. Gut 2010 59 12 1687 1693 10.1136/gut.2010.214916 20876776
77. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, et al. J Gastroenterol 2010 45 12 1272 82 10.1007/s00535-010-0278-5 20625772
78. Diagnostic and prognostic validity of golgi protein 73 in hepatocellular carcinoma. Ozkan H, Erdal H, Tutkak H, Karaeren Z, Yakut M, Yuksel O, et al. Digestion 2011 83 1-2 83 88 10.1159/000320379 21042019
79. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Abd Hamid UM, Royle L, Saldova R, Radcliffe CM, Harvey DJ, Storr SJ, et al. Glycobiology 2008 18 12 1105 1118 10.1093/glycob/cwn095 18818422 (Pubitemid 352762845)
80. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. Ang IL, Poon TC, Lai PB, Chan AT, Ngai SM, Hui AY, et al. J Proteome Res 2006 5 10 2691 2700 10.1021/pr060109r 17022640 (Pubitemid 44595171)
81. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs benign prostate disease or normal subjects. Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi M, Saito S, et al. Int J Cancer 2008 122 1 39 49 10.1002/ijc.22958 17803183 (Pubitemid 350209976)
82. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Saldova R, Wormald MR, Dwek RA, Rudd PM, Dis Markers 2008 25 4-5 219 232 19126966
83. N-glycosylation status of beta-haptoglobin in sera of patients with colon cancer, chronic inflammatory diseases and normal subjects. Park SY, Yoon SJ, Jeong YT, Kim JM, Kim JY, Bernert B, et al. Int J Cancer 2010 126 1 142 155 10.1002/ijc.24685 19551866
84. The Road from Discovery to Clinical Diagnostics: Lessons Learned From the First FDA cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers. Zhang Z, Chan DW, Cancer Epidemiol Biomarkers Prev 2010 19 12 2995 9 10.1158/1055-9965.EPI-10-0580 20962299
85. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Livingston PO, Ritter G, Calves MJ, Cancer Immunol Immunother 1989 29 3 179 184 2731184 (Pubitemid 19141694)
86. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, et al. Clin Cancer Res 2003 9 14 5214 5220 14614001 (Pubitemid 37413571)
87. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Diaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, et al. Clin Immunol 2003 107 2 80 89 10.1016/S1521-6616(03)00036-6 12763476 (Pubitemid 36579371)
88. Immunogenicity of glycolipids. Portoukalian J, Clin Rev Allergy Immunol 2000 19 1 73 78 10.1385/CRIAI:19:1:73 11064828
89. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, et al. Cancer Res 2010 70 4 1306 1313 10.1158/0008-5472.CAN-09-2893 20124478
90. Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer. Wang CC, Huang YL, Ren CT, Lin CW, Hung JT, Yu JC, et al. Proc Natl Acad Sci USA 2008 105 33 11661 11666 10.1073/pnas.0804923105 18689688
91. Lectin-based glycoproteomics to explore and analyze hepatocellular carcinoma-related glycoprotein markers. Dai Z, Zhou J, Qiu SJ, Liu YK, Fan J, Electrophoresis 2009 30 17 2957 2966 10.1002/elps.200900064 19711376
92. Glycoproteomics and glycomics investigation of membrane N-glycosylproteins from human colon carcinoma cells. Vercoutter-Edouart AS, Slomianny MC, Dekeyzer-Beseme O, Haeuw JF, Michalski JC, Proteomics 2008 8 16 3236 3256 10.1002/pmic.200800151 18651673
93. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers. Di Michele M, Marcone S, Cicchillitti L, Della Corte A, Ferlini C, Scambia G, et al. J Proteomics 2010 73 5 879 898 10.1016/j.jprot.2009.11.012 19951750
94. Functional proteomics study reveals that N-Acetylglucosaminyltransferase V reinforces the invasive/metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase-1. Kim YS, Hwang SY, Kang HY, Sohn H, Oh S, Kim JY, et al. Mol Cell Proteomics 2008 7 1 1 14 17878270 (Pubitemid 351248231)
95. Comparative quantitation of aberrant glycoforms by lectin-based glycoprotein enrichment coupled with multiple-reaction monitoring mass spectrometry. Ahn YH, Kim YS, Ji ES, Lee JY, Jung JA, Ko JH, et al. Anal Chem 2010 82 11 4441 4447 10.1021/ac1001965 20462175
96. Generation of antibodies recognizing an aberrant glycoform of human tissue inhibitor of metalloproteinase-1 (TIMP-1) using decoy immunization and phage display. Ahn HJ, Kim YS, Lee CH, Cho EW, Yoo HS, Kim SH, et al. J Biotechnol 2010 151 2 225 30 21167221
97. High expression of alpha-1-6 fucosyltransferase during rat hepatocarcinogenesis. Noda K, Miyoshi E, Uozumi N, Gao CX, Suzuki K, Hayashi N, et al. Int J Cancer 1998 75 3 444 450 10.1002/(SICI)1097-0215(19980130)75: 3<444::AID-IJC19>3.0.CO;2-8 9455807 (Pubitemid 28100049)